Drug Trial Radar · NCT05582395
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
580
Actual
Start
Dec 14, 2022
Primary completion
Mar 6, 2025
Study completion Oct 20, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Conditions
- Cardiomyopathy, Hypertrophic
Interventions
MavacamtenDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in KCCQ-23 CSS at Week 48Time frame: From First dose to week 48
- Change From Baseline in pVO2 at Week 48Time frame: From First dose to week 48
Locations
224 sites in 23 countries. Site status is shown where the registry gives one.
Local Institution - 0082
Birmingham, Alabama
Local Institution - 0458
Phoenix, Arizona
Local Institution - 0409
La Jolla, California
Local Institution - 0010
Los Angeles, California
Local Institution - 0406
San Francisco, California
Local Institution - 0079
Stanford, California
Local Institution - 0468
Gainesville, Florida
Local Institution - 0281
Tampa, Florida
Local Institution - 0092
Atlanta, Georgia
Local Institution - 0424
Indianapolis, Indiana
Local Institution - 0070
Iowa City, Iowa
Local Institution - 0410
Kansas City, Kansas
Local Institution - 0484
Louisville, Kentucky
Local Institution - 0127
Baltimore, Maryland
Local Institution - 0479
Boston, Massachusetts
Local Institution - 0500
Boston, Massachusetts
Local Institution - 0464
Ann Arbor, Michigan
Local Institution - 0064
Detroit, Michigan
Local Institution - 0455
Grand Rapids, Michigan
Local Institution - 0431
Rochester, Minnesota
Local Institution - 0461
St Louis, Missouri
Local Institution - 0435
Omaha, Nebraska
Local Institution - 0490
Morristown, New Jersey
Local Institution - 0449
Manhasset, New York
Local Institution - 0486
New York, New York
Local Institution - 0007
Stony Brook, New York
Local Institution - 0426
Valhalla, New York
Local Institution - 0094
Charlotte, North Carolina
Local Institution - 0065
Durham, North Carolina
Local Institution - 0083
Cleveland, Ohio
Local Institution - 0047
Hershey, Pennsylvania
Local Institution - 0444
Lancaster, Pennsylvania
Local Institution - 0263
Philadelphia, Pennsylvania
Local Institution - 0081
Pittsburgh, Pennsylvania
Local Institution - 0207
Germantown, Tennessee
Local Institution - 0089
Dallas, Texas
Local Institution - 0365
Dallas, Texas
Local Institution - 0492
Plano, Texas
Local Institution - 0402
Salt Lake City, Utah
Local Institution - 0478
Charlottesville, Virginia
Showing 40 of 224 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.